KNC Laboratories Co.,Ltd. (JP:6568)

:6568

6568

KNC Laboratories Co.,Ltd.

RESEARCH TOOLSreports

Want to see JP:6568 full AI Analyst Report?

KNC Laboratories Co.,Ltd. (6568) Price & Analysis

0 Followers

6568 Stock Chart & Stats

¥1124.00

¥0.00(0.00%)

At close: Jan 08 4:00 PM EST

¥1124.00

¥0.00(0.00%)

Day’s Range― - ―

52-Week Range¥971.00 - ¥1,418.00

Previous CloseN/A

Volume3.20K

Average Volume (3M)2.89K

Market Cap

¥10.04B

Enterprise Value¥9.11B

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)20.8

Beta0.51

Next Earnings

May 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.98%

Share Statistics

EPS (TTM)13.53

Shares Outstanding7,779,900

10 Day Avg. Volume3,150

30 Day Avg. Volume2,890

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)0.62

Price to Sales (P/S)1.02

P/FCF Ratio-4.61

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)208.6

Revenue Forecast (FY)¥12.00B

Bulls Say, Bears Say

Bulls Say

Balance Sheet HealthA consistently high equity ratio and low debt-to-equity indicate durable financial resilience. This strengthens the firm's ability to fund operations, absorb cyclical shocks, and pursue strategic investments without over-relying on external leverage, supporting long-term stability.

Cash Generation QualityStrong operating cash conversion demonstrates that reported earnings translate into real cash, enabling internal funding of working capital and some investment needs. Over 2–6 months this supports liquidity, lowers refinancing risk, and underpins operational sustainability.

Historical Revenue Growth & Stable Gross MarginsMulti-year revenue expansion combined with steady gross margins suggests solid product demand and maintained cost competitiveness or pricing power. These structural strengths support durable cash flows and provide a foundation for recovery after temporary downturns.

Bears Say

Recent Revenue DeclineA revenue drop in the latest period signals either softening end-market demand or execution challenges. If persistent, declining top-line undermines operating leverage, reduces reinvestment capacity, and can pressure margins and returns over the medium term.

Negative Free Cash FlowSustained negative free cash flow from elevated capex reduces financial flexibility and may necessitate external financing or cutbacks in shareholder returns. Over months this raises execution risk if capex fails to generate commensurate incremental returns.

Profitability PressureEroding EBIT and net margins point to rising costs, pricing pressure, or mix shifts. If structural, margin compression will lower ROE and free cash generation, limiting the company's capacity to invest, pay dividends, or build reserves over the medium term.

6568 FAQ

What was KNC Laboratories Co.,Ltd.’s price range in the past 12 months?

KNC Laboratories Co.,Ltd. lowest stock price was ¥971.00 and its highest was ¥1418.00 in the past 12 months.

What is KNC Laboratories Co.,Ltd.’s market cap?

KNC Laboratories Co.,Ltd.’s market cap is ¥10.04B.

When is KNC Laboratories Co.,Ltd.’s upcoming earnings report date?

KNC Laboratories Co.,Ltd.’s upcoming earnings report date is May 19, 2026 which is in 12 days.

How were KNC Laboratories Co.,Ltd.’s earnings last quarter?

KNC Laboratories Co.,Ltd. released its earnings results on Feb 13, 2026. The company reported ¥13.53 earnings per share for the quarter, beating the consensus estimate of N/A by ¥13.53.

Is KNC Laboratories Co.,Ltd. overvalued?

According to Wall Street analysts KNC Laboratories Co.,Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does KNC Laboratories Co.,Ltd. pay dividends?

KNC Laboratories Co.,Ltd. pays a Semiannually dividend of ¥17 which represents an annual dividend yield of 2.98%. See more information on KNC Laboratories Co.,Ltd. dividends here

What is KNC Laboratories Co.,Ltd.’s EPS estimate?

KNC Laboratories Co.,Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does KNC Laboratories Co.,Ltd. have?

KNC Laboratories Co.,Ltd. has 7,779,900 shares outstanding.

What happened to KNC Laboratories Co.,Ltd.’s price movement after its last earnings report?

KNC Laboratories Co.,Ltd. reported an EPS of ¥13.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -1.556%.

Which hedge fund is a major shareholder of KNC Laboratories Co.,Ltd.?

Currently, no hedge funds are holding shares in JP:6568

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

KNC Laboratories Co.,Ltd.

KNC Laboratories Co., Ltd. engages in the research, development, and production solutions of organic chemicals in Japan. The company offers products for use in the pharmaceutical, electronic-chemical, agrochemical, energy, and environment fields. It offers support services for drugs and functional chemicals. The company was incorporated in 1985 and is headquartered in Kobe, Japan.